|
Pneumococcal vaccines Accelerated Development and Introduction Plan (PnemoADIP) is a small team based at Johns Hopkins Bloomberg School of Public Health and is supported by a $30 million grant from the Global Alliance for Vaccines and Immunization. Its main goal is to improve child survival and health by accelerating the evaluation of and access to new, lifesaving pneumococcal vaccines for the world's children.〔(【引用サイトリンク】title=PneumoADIP – Pneumococcal vaccines Accelerated Development and Introduction Plan )〕 PneumoADIP aims to achieve its goals through partnerships with countries, donors, academia, international organizations, and industry. PneumoADIP coordinates its activities through a strategic alliance with the World Health Organization. PneumoADIP's Executive Director is Orin Levine. In April 2009, Rwanda became the first low-income country to introduce the pneumococcal vaccine Prevnar into its routine schedule for children. This introduction is expected to save thousands of lives each year and dramatically decrease the economic burden of this disease. This introduction marked a major milestone for PneumoADIP and for global health. Historically it has taken 15–25 years for new vaccines to reach children in low-income countries. Rwanda has introduced the vaccine only 9 years after it was initially licensed in the U.S. and only three years after universal introduction began in France, Germany, and the United Kingdom. PnemoADIP's Director of Alliances and Information is Lois Privor-Dumm. PneumoADIP is a member of the Global Coalition Against Pneumonia and supports World Pneumonia Day on November 2, 2009. ==References== 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「PneumoADIP」の詳細全文を読む スポンサード リンク
|